TABLE 4.
Scores of quality of life (QLQ-C30 and QLQ-MY20) according to sensory CIPN, and correlation with sensory and motor scores of the QLQ-CIPN20.
| All the patients | No sensory CIPN | Sensory CIPN | Effect size [CI 95%] | Correlations sensory scores | Correlations motor scores | |
| QLQ-C30 | ||||||
| Global health status | 63.5 ± 24.1 | 68.1 ± 22.7 | 51.9 ± 24.3* | −0.69 [−1.24; −0.14] | −0.52* | −0.60* |
| Physical functioning | 74.5 ± 23.0 | 79.5 ± 22.5 | 60.0 ± 18.3*** | −0.90 [−1.46; −0.33] | −0.66* | −0.65* |
| Role functioning | 75.8 ± 29.7 | 83.0 ± 25.8 | 54.9 ± 31.0** | −1.02 [−1.59; −0.44] | −0.56* | −0.59* |
| Emotional functioning | 74.8 ± 26.2 | 77.8 ± 26.1 | 67.0 ± 25.5* | −0.42 [−0.95; 0.13] | −0.47* | −0.58* |
| Cognitive functioning | 83.3 ± 22.5 | 87.5 ± 19.3 | 72.2 ± 26.8* | −0.70 [−1.25; −0.15] | −0.48* | −0.59* |
| Social functioning | 71.3 ± 27.7 | 77.3 ± 25.6 | 55.6 ± 27.4** | −0.82 [−1.37; −0.26] | −0.59* | −0.70* |
| Fatigue | 36.5 ± 31.4 | 30.2 ± 30.1 | 53.7 ± 28.8** | 0.78 [0.23; 1.33] | 0.51 | 0.65* |
| Nausea and vomiting | 7.1 ± 17.8 | 6.5 ± 14.8 | 8.8 ± 25.1 | 0.13 [−0.42; 0.67] | 0.11 | 0.30* |
| Pain | 25.0 ± 27.6 | 18.1 ± 24.0 | 43.5 ± 28.7c | 0.99 [0.43; 1.55] | 0.54* | 0.58* |
| Dyspnea | 28.3 ± 29.4 | 27.2 ± 26.9 | 31.4 ± 36.3 | 0.14 [−0.41; 0.68] | 0.19 | 0.29* |
| Insomnia | 35.4 ± 35.0 | 27.9 ± 32.9 | 56.9 ± 32.8** | 0.87 [0.30; 1.43] | 0.49* | 0.61* |
| Appetite loss | 18.7 ± 31.6 | 16.3 ± 29.7 | 25.5 ± 36.4 | 0.29 [−0.26; 0.83] | 0.19 | 0.40* |
| Constipation | 27.8 ± 33.9 | 24.5 ± 31.7 | 37.2 ± 38.9 | 0.37 [−0.18; 0.92] | 0.27* | 0.37* |
| Diarrhea | 16.4 ± 29.2 | 15.0 ± 28.1 | 20.4 ± 32.6 | 0.18 [−0.35; 0.72] | 0.13 | 0.36* |
| Financial difficulties | 8.6 ± 21.3 | 5.6 ± 17.3 | 16.7 ± 28.6 | 0.52 [−0.02; 1.07] | 0.29* | 0.35* |
| QLQ-MY20 | ||||||
| Disease symptoms | 20.8 ± 20.5 | 15.8 ± 16.2 | 34.6 ± 25.0** | 0.98 [0.42; 1.54] | 0.55* | 0.58* |
| Side effects of treatment | 22.4 ± 21.1 | 16.3 ± 17.4 | 38.9 ± 21.8*** | 1.19 [0.62; 1.76] | 0.74* | 0.76* |
| Body image | 75.4 ± 34.0 | 83.0 ± 30.2 | 55.6 ± 36.1** | −0.85 [−1.40; −0.29] | −0.44* | −0.62* |
| Future perspective | 61.2 ± 31.7 | 67.8 ± 29.2 | 43.8 ± 32.0** | −0.79 [−1.34; −0.23] | −0.47* | −0.49* |
The results present the Spearman coefficient (correlation) between the sensory and motor scores of the QLQ-CIPN20 and the scores of the QLQ-C30 and the scores of the QLQ-MY20. The mean (±standard deviation) scores of the QLQ-C30 dimensions and the QLQ-MY20 dimensions are presented for all the patients, the patients with no sensory CIPN and the patients with a sensory CIPN. Effect size (Hedge coefficient) and 95% interval confidence of this comparison are presented.
p < 0.05.
p < 0.01.
p < 0.001.
No sensory CIPN vs. sensory CIPN. Statistical analyzes were performed using student or Mann–Whitney tests for the comparisons between sensory CIPN (yes vs no), and Spearman correlation coefficient to the study of relationship between QLQ-C30, QLQ-MY20 and sensory/motor scores of the QLQ-CIPN20.